Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Sage shares surge as...

    Sage shares surge as depression drug succeeds in mid-stage trial

    Written by Ruby Khatun Khatun Published On 2017-12-09T09:30:39+05:30  |  Updated On 13 Aug 2021 5:29 PM IST

    Drug developer Sage Therapeutics Inc's shares soared as much as 85 percent to a record high on Thursday after its experimental drug to reduce the symptoms of depression succeeded in a mid-stage trial.


    Sage's shares were up 73 percent at $159, on track to add about $2.75 billion to the company's market capitalization.


    This is Sage's second success in as many months. The company's postpartum depression drug aced two key studies in November, paving the way for it to bring to market the first FDA-approved treatment for the disorder.



    Data reported on Thursday showed that the drug, SAGE-217, was statistically significant in reducing symptoms of depression, compared to a placebo.

    "If we can substantiate these findings in Phase 3, this could be an important first-line therapeutic option for everybody with depression," Chief Executive Jeff Jonas told Reuters.


    Pfizer Inc's Pristiq, Takeda Pharmaceutical Co Ltd, and Lundbeck's Brintellix have been approved in the United States for the treatment of adults with major depression.


    Alkermes Plc, Eli Lilly and Co and Allergan Plc all have their drugs in late-stage trials for the treatment of depression.


    Analysts said Thursday's data backs the drug's mechanism, which is different from other treatments approved by the FDA in the last two decades.


    "SAGE-217 would be an important drug as it offers a new mechanism in an area where the vast majority of options generally modulate the same pathways," Leerink Research's Paul Matteis wrote in a client note.


    Sage's drug works by selecting and binding together the GABA receptors - which manage the flow of information in the brain - to help put brakes on nerve activity and thereby calming the brain.


    Any dysfunction to the receptors can cause a variety of central nervous system (CNS) disorders.


    CEO Jonas said the company would not seek to partner with big pharma companies.


    "What would be the goal of a big pharma partner besides cash, we can obtain that from the market," Jonas said, adding the biotech was well-positioned to grow into a leading CNS company.


    Sage had $134.9 million in cash and cash equivalents as of Sept. 30.


    The company's shares had risen 80 percent this year to Wednesday's close.




    (Reporting by Akankshita Mukhopadhyay and Divya Grover in Bengaluru; Editing by Shounak Dasgupta and Sriraj Kalluvila)



    Alkermes PlcAllerganCentral Nervous Systemdepressiondepression drugEli Lillyexperimental drugJeff Jonasmid-stage trialPfizerPristiqSage TherapeuticsSAGE-217SharessucceedsTakeda Pharmaceutical
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok